- Home
- DLXY vs PHIO Comparison
DLXY vs PHIO Comparison
Compare DLXY & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DLXY | PHIO |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 12.3M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | DLXY | PHIO |
|---|---|---|
| Price | $0.88 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | 55.0K | ★ 374.9K |
| Earning Date | 12-30-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1077.13 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $273,155,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.61 | $0.97 |
| 52 Week High | $7.16 | $9.79 |
Technical Indicators
Market Signals| Indicator | DLXY | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.48 |
| Support Level | N/A | $1.00 |
| Resistance Level | N/A | $1.22 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 68.23 |
Price Performance
Historical ComparisonAbout DLXY Delixy Holdings Limited Ordinary Shares
Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.